Weekly Recap | Adma Biologics +3.62%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Adma Biologics (ADMA) rose 3.62% this week to close at $9.72, while the S&P 500 slipped 0.27%, leaving the stock ahead of the benchmark by about 3.89 percentage points. The move was a fade: Monday (Sep 28) opened soft and rallied to $10.12, Tuesday through Thursday stayed in a narrow $9.93-$10.03 range, and Friday (Oct 2) tagged the week’s high of $10.285 before retreating to $9.72. Average daily volume of around 3.
The Week
Adma Biologics (ADMA) rose 3.62% this week to close at $9.72, while the S&P 500 slipped 0.27%, leaving the stock ahead of the benchmark by about 3.89 percentage points. The move was a fade: Monday (Sep 28) opened soft and rallied to $10.12, Tuesday through Thursday stayed in a narrow $9.93-$10.03 range, and Friday (Oct 2) tagged the week’s high of $10.285 before retreating to $9.72. Average daily volume of around 3.3m shares ran 35% above its recent median, with no company-specific catalyst and price action tracking sector sentiment.
Analyst Ratings
Four brokers cover the stock: two rate it buy, one overweight and one hold, with no underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $17, about 74.9% above the $9.72 close. Targets range from $12 to $21, nearly a two-fold spread that points to wide disagreement. Within biotech, the stock ranks 312 out of 507, putting it in the middle-to-lower band.
The Week Ahead
Macro data dominates: Monday (Oct 5) brings the S&P Global services PMI final and ISM non-manufacturing PMI, Tuesday (Oct 6) the US trade balance, and Wednesday (Oct 7) EIA weekly crude and Cushing inventory reports. If this week’s gene-editing sentiment spills over, plasma-focused names like ADMA could feel the rotation. No company-specific events are on the calendar.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.